Cancer is not a single disease but a collection of more than 200 related conditions that share a common root: cells in the body begin growing without the usual controls. In a healthy body, cells divide in an orderly way, stop when they should, and die on schedule. Cancer develops when genetic or chemical changes break those rules, allowing cells to multiply unchecked and, in many cases, invade tissues far from where they started. Researchers have distilled the complexity of cancer into a set of core capabilities that tumor cells acquire over time, from sustained growth signaling and resistance to cell death to immune evasion and the ability to spread to distant organs.
How a Normal Cell Becomes Cancerous
Your cells have a built-in system of brakes and traffic lights that govern when they divide and when they stop. These checkpoints ensure that each step of cell division happens only once and in the right sequence; mutations in the proteins that run those checkpoints are found across virtually all cancer types.1PubMed Central. Cell cycle checkpoints and their inactivation in human cancer When those controls fail, a cell can keep copying itself even when it shouldn’t.
Two categories of genes sit at the center of this breakdown. The first are proto-oncogenes, normal genes that help cells grow. When a proto-oncogene picks up certain mutations, it becomes an oncogene: stuck in the “on” position, constantly telling the cell to divide. The second category is tumor suppressor genes, which act as brakes on growth. When these are knocked out, the cell loses its ability to slow down or self-destruct. The accumulation of activated oncogenes and inactivated tumor suppressors is the driving force that turns a normal cell into a malignant one. Both types of damage have been directly observed, for instance, in human colon and lung tumors.2PubMed Central. Role of proto-oncogene activation in carcinogenesis
Healthy cells also have a self-destruct program that kicks in when something goes badly wrong. Cancer cells find ways to disable or override this program, either by boosting their survival machinery, turning down the death signals, or both.3PubMed Central. Evading apoptosis in cancer The result is cells that refuse to die when they should, accumulating further damage with every round of division.
On top of all this, DNA repair systems normally catch and fix mistakes before they become permanent mutations. When repair pathways themselves are faulty, the rate of new mutations climbs steeply, feeding a cycle of increasing genetic instability that accelerates cancer development.4PubMed Central. DNA Damage/Repair Management in Cancers Ironically, this same reliance on whatever repair capacity remains can become a vulnerability that treatments exploit.5PubMed Central. DNA repair defects in cancer and therapeutic opportunities
Beyond Mutations: How Genes Get Silenced Without Changing
Not every cancer-driving change involves a mutation in the DNA code itself. Cells also regulate gene activity through chemical tags added on top of DNA and its packaging proteins. These are called epigenetic changes, and they can switch genes off without altering a single letter of the genetic sequence. In cancer, a common pattern emerges: tumor suppressor genes get shut down by heavy chemical tagging of their control regions, silencing them just as effectively as a mutation would.6PubMed. Epigenetic gene silencing in cancer initiation and progression
This kind of silencing has been linked to breast cancer, liver cancer, prostate cancer, and bladder cancer, among others.7Cell Death Discovery. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine What makes epigenetic changes particularly interesting is that, unlike mutations, they are potentially reversible. That feature has made them a target for newer therapies that aim to “reactivate” silenced tumor suppressors. The interplay between DNA tagging and protein packaging modifications is complex, and researchers are still working out which comes first in the chain of events that locks a gene into silence.8Mutation Research/Reviews in Mutation Research. Epigenetic interplay between histone modifications and DNA methylation in gene silencing
How Cancer Cells Rewire Their Energy Use
Normal cells get most of their energy through a highly efficient process that requires oxygen. Cancer cells, even when oxygen is available, lean heavily on a less efficient method that rapidly converts sugar into a byproduct called lactate. This shift was first noticed almost a century ago and is known as the Warburg effect. Cancer cells ramp up their glucose intake far beyond what a normal cell needs.9PubMed Central. The Warburg Effect: How Does it Benefit Cancer Cells?
Why would a cell choose the less efficient route? The answer lies in what fast-growing cells actually need. Dividing cells do not just need energy; they need raw materials to build new copies of themselves, including building blocks for DNA, proteins, and cell membranes. The less efficient energy pathway generates many of those building blocks as side products, making it well suited to the demands of rapid multiplication.10PubMed Central. Understanding the Warburg effect: the metabolic requirements of cell proliferation This metabolic shift also supports survival and the ability to spread.11PubMed. Revisiting the biological role of the Warburg effect: Evolving perspectives on cancer metabolism The voracious sugar appetite of tumors is, incidentally, the basis for PET scans: patients receive a radioactive sugar tracer, and the areas that light up brightest tend to be the most metabolically active tumor sites.
The Tumor Microenvironment
A tumor is not just a ball of cancer cells. From early in its growth, a reciprocal relationship develops between the cancer cells and the normal tissue around them. Cancer cells recruit blood vessel cells, immune cells, and structural support cells into what is known as the tumor microenvironment, and these recruited cells actively help the tumor survive, grow, and eventually spread.12PubMed Central. The tumor microenvironment
One of the most critical services the microenvironment provides is a blood supply. A tumor that grows beyond a tiny size needs its own network of blood vessels to deliver oxygen and nutrients. Cancer cells trigger the growth of new blood vessels by releasing signaling molecules that stimulate nearby vessel-lining cells to multiply, migrate, and form new capillary branches.13PubMed Central. Tumor angiogenesis: causes, consequences, challenges and opportunities The blood vessels that tumors grow tend to be leaky and disorganized compared to normal vessels, which creates an unusual tissue environment and can paradoxically make it harder for drug treatments to penetrate the tumor evenly.
How Cancer Spreads to Other Organs
Metastasis, the spread of cancer from its original site to distant parts of the body, is what makes the disease so dangerous. Most cancer deaths are caused not by the primary tumor but by secondary growths in vital organs. The journey from a stationary tumor cell to a colony in a distant organ is a multistep obstacle course, and most cells that attempt it do not survive.
The process often begins with a change in behavior at the cellular level. Cells that are normally anchored in place and tightly connected to their neighbors undergo a shift that makes them more mobile and invasive. This transition is a normal part of wound healing and embryonic development, but cancer cells hijack it to break free from the primary tumor.14PubMed Central. Molecular mechanisms of epithelial-mesenchymal transition Once mobile, these cells can penetrate nearby blood or lymph vessels and travel through the circulation. During that journey, they face shear forces from blood flow, attacks from immune cells, and the challenge of finding a hospitable destination.
Where cancer cells end up is not random. Most cancers show a strong preference for certain organs, a phenomenon called organotropism. Breast cancer, for example, commonly spreads to bones, lungs, liver, and brain, while colon cancer tends to metastasize to the liver. This pattern depends on a combination of the tumor’s own properties and the unique features of each destination organ.15PubMed Central. Metastasis Organotropism: Redefining the Congenial Soil Research increasingly suggests that tumors can prepare distant sites in advance, sending out molecular signals that condition the target organ to be more receptive before cancer cells even arrive.16PubMed. Biomechanical networks of the pre-metastatic niche: Decoding biophysical determinants of tumor metastatic organotropism
How Tumors Evade the Immune System
Your immune system constantly patrols for abnormal cells, and in theory, a cancer cell covered in unfamiliar proteins should set off alarm bells. In practice, tumors deploy several strategies to avoid detection and destruction. They can restrict antigen recognition, actively suppress immune responses, and exhaust the T cells that are supposed to kill them.17PubMed Central. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment
One approach is camouflage. Cancer cells can lose or damage the machinery they need to display abnormal proteins on their surface. Without those markers visible, immune cells simply do not recognize the cancer cell as a threat. In other cases, tumors use a more direct tactic, displaying molecules on their surface that essentially tell immune cells to stand down. The best-known example is PD-L1, a surface protein that interacts with a receptor on killer T cells and suppresses their attack function.18Cancer Cell. The three Cs of cancer immune evasion Modern immunotherapy drugs work by blocking that interaction, essentially removing the “off switch” so T cells can resume attacking.
Dormancy and Why Cancer Can Return Years Later
One of the more unsettling aspects of cancer is its ability to recur years or even decades after apparently successful treatment. This happens because some cancer cells can enter a dormant state, essentially going quiet and ceasing to grow while remaining alive in the body. Three main models explain this: the cells may sit in a tissue where the blood supply is not sufficient to support a growing tumor, the immune system may keep them in check without fully eliminating them, or individual cells may simply stop dividing and enter a kind of hibernation.19PubMed Central. Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis
A subpopulation of cells known as cancer stem cells appears to play a role in this process. These cells are thought to be especially adept at self-renewal, resistance to therapy, and dormancy, which may explain why they can seed a new tumor long after the bulk of the original growth has been destroyed.20PubMed Central. Emerging Role of Autophagy in Governing Cellular Dormancy, Metabolic Functions, and Therapeutic Responses of Cancer Stem Cells Figuring out how to detect and eliminate dormant cells remains one of the harder open problems in oncology.
Tumor Evolution and Internal Diversity
A single tumor is rarely a uniform mass. As cancer cells divide and acquire new mutations, different subgroups within the same tumor end up with different genetic profiles. This internal diversity means that a drug effective against one population of cells may leave another population untouched. The principles of Darwinian evolution apply directly: genetically varied cells compete for resources, and those best suited to their environment, including the environment created by treatment, survive and expand.21Cell. Intratumor Heterogeneity and Tumor Evolution This is a major reason why cancers develop resistance to therapy over time, and it underlies the push toward combination treatments that hit multiple targets at once.22PubMed Central. Tumor heterogeneity, clonal evolution, and therapy resistance: an opportunity for multitargeting therapy
What Triggers Cancer: Carcinogens, Viruses, and Inherited Risk
The mutations and epigenetic changes behind cancer do not appear from nowhere. External agents called carcinogens cause various forms of DNA damage, including breaks in the DNA strand, chemical attachments that distort the DNA structure, and cross-links that jam the replication machinery.23PubMed Central. Carcinogens and DNA damage Common carcinogens include ultraviolet light from the sun, ionizing radiation, and chemicals found in tobacco smoke. Tobacco smoke alone contains more than 70 known carcinogens, some of which damage DNA directly while others require the body’s own metabolism to convert them into harmful forms.24PubMed Central. DNA damage, DNA repair and carcinogenicity: Tobacco smoke versus electronic cigarette aerosol Among the most studied is benzo[a]pyrene, a chemical in cigarette smoke that forms DNA adducts after metabolic activation and is considered a major contributor to lung cancer.25PubMed Central. Human genome-wide repair map of DNA damage caused by the cigarette smoke carcinogen benzo[a]pyrene
Viruses are another route. Certain viruses, sometimes called oncoviruses, produce proteins that interfere directly with the host cell’s growth controls. These viral proteins can push resting cells into active division and disrupt checkpoint regulation, promoting uncontrolled proliferation and helping the cell evade immune surveillance.26PubMed Central. The Impact of Oncogenic Viruses on Cancer Development: A Narrative Review Well-known examples include human papillomavirus (HPV), linked to cervical and several other cancers, and hepatitis B and C viruses, linked to liver cancer.
Some people inherit a head start toward cancer. Hereditary cancer syndromes affect at least two percent of apparently healthy people, who carry gene variants that strongly predispose them to certain malignancies. In most of these cases, one copy of a tumor suppressor gene is already defective from birth; cancer develops when the remaining working copy is knocked out by a random event later in life.27PubMed Central. Hereditary cancer syndromes The BRCA1 and BRCA2 genes are perhaps the best-known examples, but dozens of other hereditary syndromes exist. Having such a variant does not make cancer inevitable, but it does substantially raise the odds and often shifts the age at which cancers appear.
The Major Types and How They Are Classified
Cancers are broadly classified by the type of cell or tissue where they originate. Understanding these categories matters because treatment, behavior, and prognosis differ dramatically between them.
- Carcinomas: These arise from epithelial cells, the cells that line your organs, skin, and glands. They are the most common group, accounting for the vast majority of cancer diagnoses. Subtypes include adenocarcinomas (from glandular tissue, such as most breast and colon cancers) and squamous cell carcinomas (from flat surface cells, as in some lung and skin cancers).
- Sarcomas: These develop in bone, cartilage, fat, muscle, or other connective tissues. They are much less common than carcinomas and tend to occur in younger populations.
- Leukemias: Cancers of the blood-forming tissue, mainly the bone marrow. They result in large numbers of abnormal white blood cells flooding the bloodstream and do not form solid tumors.
- Lymphomas: These originate in the lymphatic system, particularly in lymph nodes. Hodgkin lymphoma and non-Hodgkin lymphoma are the two main branches.
- Central nervous system cancers: Tumors that arise in the brain or spinal cord. Gliomas, which develop from the supportive cells of the brain, are the most common type in adults.
Beyond tissue of origin, cancers are increasingly classified by molecular and genetic features. Two lung tumors that look identical under a microscope may have entirely different mutation profiles and respond to different drugs. Molecular profiling has been especially transformative for cancers with targeted therapy options, allowing oncologists to match treatments to the specific genetic defects driving an individual’s tumor rather than relying solely on where in the body it arose.
The Hallmarks Framework
Researchers have organized the many capabilities cancer cells acquire into a conceptual framework known as the hallmarks of cancer. Originally proposed as six core capabilities, including sustained growth signaling, evading growth suppressors, resisting cell death, unlimited replication, new blood vessel formation, and invasion and metastasis, the framework has since been expanded. Genome instability and inflammation were recognized as underlying conditions that enable the other hallmarks, and two additional capabilities, reprogramming energy metabolism and evading the immune system, were added as emerging hallmarks.28Cell. Hallmarks of Cancer: The Next Generation
More recently, the framework has continued to evolve. New dimensions include the ability of cancer cells to shift between different cell identities, non-mutation-based changes in gene expression, and even the possible influence of the body’s microbial communities on tumor development. Senescent cells, old cells that have stopped dividing but remain metabolically active, are also now recognized as meaningful players in the tissue surrounding a tumor.29PubMed. Hallmarks of Cancer: New Dimensions The hallmarks framework is not a checklist that every tumor completes in order; it is a way to make sense of the staggering variety of ways different cancers behave.
Why Large Animals Do Not Get More Cancer
If cancer starts with a single cell going wrong, you might expect that animals with far more cells would get cancer far more often. A whale has trillions more cells than a mouse, which means trillions more opportunities for a mutation to arise. Yet large, long-lived animals do not have elevated cancer rates compared to small ones. This counterintuitive observation is known as Peto’s paradox, and it suggests that natural cancer-suppression mechanisms can be far more powerful than those in human cells.30PubMed Central. Peto’s Paradox: evolution’s prescription for cancer prevention
Researchers looking across mammalian genomes have not found a straightforward increase in the number of tumor suppressor genes as body size goes up. Instead, different species appear to have evolved their own solutions. Elephants, for example, carry extra copies of the TP53 gene, one of the most important tumor suppressors. Horses show amplification of a different protective gene, and certain bat species have yet another.31PubMed Central. Solutions to Peto’s paradox revealed by mathematical modelling and cross-species cancer gene analysis These findings hint that there is no single universal “fix” for cancer risk. Evolution has arrived at multiple independent strategies, each tailored to the biology of a given species, which is a hopeful observation for researchers looking for new angles on prevention and treatment.